<DOC>
	<DOCNO>NCT03031483</DOCNO>
	<brief_summary>Patients lymphoid tissue lymphoma mucosa-associated ( MALT ) standard treatment radiotherapy , chemotherapy / immunotherapy show lack efficacy</brief_summary>
	<brief_title>Clarithromycin + Lenalidomide Combination : Full Oral Treatment Patients With Relapsed/Refractory Extranodal Marginal Zone Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<criteria>Histologically verify diagnosis MALT lymphoma arise extranodal site Disease refractory first great relapse prior radiotherapy and/ chemotherapy and/or immunotherapy Measurable nonmeasurable lesion response nevertheless evaluable nonimaging mean ( e.g. , gastric bone marrow infiltration ) Ann Arbor Stage IIV ECOG performance status 0 , 1 2 Age ≥ 18 year Life expectancy least 3 month Adequate haematological status : ANC ( absolute neutrophil count [ segment + band ] ) ≥1.0 x 109/L , platelet count ≥ 75 x 109/L , haemoglobin ≥8 g/dL . Adequate cardiac , renal liver function test ( LVEF &gt; 40 % , serum creatinine &lt; 2.5 mg/dl , ALAT ASAT &lt; 2.5 x upper limit normal range , alkaline phosphatase &lt; 2.5 x upper limit normal range , serum bilirubin &lt; 2.0 mg/dl ) Patient must willing able comply protocol entire study duration Female patient childbearing potential must agree use , able comply , effective contraception agree medically supervised pregnancy test prior start study treatment therapy Male patient must agree always use condom sexual contact female reproductive potential agree donate sperm take lenalidomide Patient must agree abstain donate blood take study drug therapy Patient must agree share study medication another person return unused study drug investigator Patient must willing able comply protocol Patient must capable understanding Lymphoma histology MALT lymphoma MALT lymphoma diffuse large cell lymphoma ( `` high grade lymphoma '' ) component Use investigational agent within 28 day prior initiation treatment History malignancy squamous cell carcinoma , basal cell carcinoma skin carcinoma situ uterine cervix within last 5 year unless complete remission since least 3 year Dependency red blood cell and/or platelet transfusion HBsAg positivity Evidence central nervous system involvement A history uncontrolled seizure , central nervous system disorder psychiatric disability judge investigator clinically significant adversely affect compliance study drug Severe peripheral polyneuropathy Clinically significant cardiac disease ( e.g . congestive heart failure , symptomatic coronary artery disease cardiac arrhythmia well controlled medication ) myocardial infarction within last 6 month and/or long QTsyndrome HIV seropositivity Presence active opportunistic infection Pregnancy lactation Uncontrolled diabetes mellitus Preexisting thromboembolic condition study entry Known hypersensitivity thalidomide lenalidomide macrolide antibiotic Presence contraindication report Summary Product Characteristics ( SmPC ) Clarithromycin Hypersensitivity active principle and/or excipient accord contraindication report SmPC clarithromycin Investigator 's Brochure ( IB ) lenalidomide</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>